CSL Behring to acquire stem cell therapy biotech firm – The Pharma Letter (registration)
|
CSL Behring to acquire stem cell therapy biotech firm
The Pharma Letter (registration) Blood products and vaccines specialist CSL Behring, a subsidiary of Australia's CSL Limited (ASX: CSL), has agreed to acquire Calimmune, a US biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy … |
